

Index

A

Advanced glycation end products (AGEs), 6, 19–20, 23

Adventitia

fibroblasts, 19

TGF- β 1 expression, 23

tunica, 5

AGEs *See* Advanced glycation end products (AGEs)

AIx *See* Augmentation index (AIx)

Anthocyanins and betalains (pigments), 46–47

Antioxidant vitamins (C and E), 50

Aortic pulse wave velocity (aPWV), 15, 16, 18

and abdominal visceral fat, 32

cardiorespiratory fitness, 33

GFR, 35

nascent clinical outcome measure, 27

normal/reference population, 28

pulse pressure amplification, 30

Applanation tonometry technique, 8

aPWV *See* Aortic pulse wave velocity (aPWV)

Arterial stiffness

in adults, 6–8

AIx, 9

applanation tonometry, 8

central pulse pressure, 8–9

IMT, 9–10

pulse pressure, 6

PWV *see* Pulse wave velocity (PWV)

SphygmoCor system, 8

volume and pressure changes, 6

aging, 18

mouse models, 15

process, 3

aortic function and physiology, 2, 3

aPWV and *ex vivo* mechanical testing, 15

arteriosclerosis, 1

atherosclerosis, 1 *see also* Cardiovascular disease (CVD)

cardiovascular health, systemic circulation, 3

cellular changes, 20–21

cellular and molecular events, 15

compositional changes

AGEs, 19–20

calcium, 20

collagen, 19

elastin, 19

CVD-related events, 1

description, 1

destiffening, 43, 44

detrimental effects, 43

elastic arteries, 3–4

functional changes, 5

blood pressure, 16

endothelium-dependent dilation, 17–18

smooth muscle function, 17

gross morphological changes, 18

muscular arteries, 4

organ damage

brain, 35

heart, 34–35

kidneys, 35–36, *see also* Signaling mechanisms

smooth muscle function, 4

structural changes, 5–6

Arteriosclerosis, 1, 2, 11, 48

Atherosclerosis, 1, 2, 10, 29, 32

Augmentation index (AIx)

B

B-PP *See* Brachial pulse pressure (B-PP)
 Brachial pulse pressure (B-PP), 30

C

Cardiorespiratory fitness
 chronic, regular physical activity, 33
 occipitoparietal perfusion and cognitive
 composite scores, 33
 VO₂ peak, total and LDL cholesterol, 33
 Cardiovascular disease (CVD)
 aPWV, 27
 arterial stiffness, epidemiology, 27, 28
 central hemodynamic parameters, 10
 coronary perfusion pressure, 11
 mortality, cause of, 27
 muscular peripheral artery, 10
 peripheral blood pressure, 10
 SBP, central pulse pressure and left
 ventricle, 10
 Carotid-femoral PWV (cfPWV), 7
 Central pulse pressure (C-PP), 8–9, 30
 cfPWV *See* Carotid-femoral PWV (cfPWV)
 Chronic exercise training
 aerobic exercise, 50
 aPWV reductions, 52
 CVD risk factors, 52
 destiffen arteries, 51
 eNOS, 51
 Collagen
 age-related arterial stiffening, 19
 arterial collagen II expression, 19
 collagenase-resistant animal, 19
 and elastin fibers, 4
 extracellular protein, 19
 C-PP *See* Central pulse pressure (C-PP)

D

DASH *See* Dietary Approaches to Stop
 Hypertension (DASH)
 DBP *See* Diastolic blood pressure (DBP)
 Diastolic blood pressure (DBP), 11
 Dietary Approaches to Stop Hypertension
 (DASH), 49

E

ECM *See* Extracellular matrix (ECM) proteins
 EDD *See* Endothelium dependent dilation
 (EDD)
 EID *See* Endothelium-independent dilation (EID)
 Elastin, 19
 Endothelium dependent dilation (EDD), 17

Endothelium-independent dilation
 (EID), 17
 Epidemiology, arterial stiffness
 aging
 aPWV, 28, 29
 BLSA, 28
 obesity and diabetes, 29
 physiological mechanisms, 28
 primary determinant, cardiovascular
 health, 28
 body composition, 31–32
 habitual exercise training
 cardiorespiratory fitness, 33
 strength training, 33–34
 race, 30–31
 sex
 atherosclerosis, hypertension, angina
 and stroke, 29
 B-PP/C-PP ratio, 30
 HFpEF, 29
 MESA project, 30
Ex vivo mechanical testing, 16
 Extracellular matrix (ECM) proteins, 5

F

Flavonoids, 45
 Functional foods, 44, 45

H

Heart failure with preserved ejection fraction
 (HFpEF), 29
 Heart healthy diets, 44
 HFpEF *See* Heart failure with preserved
 ejection fraction (HFpEF)

I

Impaired endothelium-dependent dilation,
 17–18
 Impaired smooth muscle function, 17
 IMT *See* Intima-media thickness (IMT)
 Intima-media thickness (IMT), 18
 aortic morphology, 9
 carotid IMT thickening, 10
 local arterial stiffness, 9
 MESA study, 10
 Isoflavones, 46

L

Large elastic arteries
 blood pressure, 4
 distal aorta, 3

- and collagen fibers, 4
 - composition, 3
 - macro-vasculature, 3
- Lifestyle modifications, CVD
 - health benefits, 52
 - prevention and treatment, 52
 - weight loss, 52–53
- M**
- MESA *See* Multi-Ethnic Study of Atherosclerosis (MESA) project
- Micronutrients
 - antioxidant vitamins (C and E), 50
 - sodium restriction, 48–49
- Multi-Ethnic Study of Atherosclerosis (MESA) project, 30
- Muscular arteries, 4
- N**
- NFκB *See* Nuclear factor kappa B (NFκB) transcription factor
- Nitric oxide (NO), 22
- Nuclear factor kappa B (NFκB) transcription factor, 22
- Nutraceuticals, 44
- O**
- Omega-3 fatty acids
 - cigarette smoking, 48
 - marine sources, 47
 - Mediterranean diets, 47
 - metabolic syndrome, 48
 - supplementation, 48
- Oxidative stress
 - definition, 21
 - elastin content, 22
 - SOD antioxidant defense system, 21
- P**
- Polyphenolic compounds
 - anthocyanins and betalains (pigments), 46–47
 - classes, 45
 - flavonoids, 45
 - isoflavones, 46
- Pulse wave velocity (PWV)
 - aorta/carotid arteries, 6
 - cfPWV, 7
 - Moens-Kortweg equation, 6
 - pulse wave transit time, 7
- R**
- RAGE *See* Receptor of advanced glycation end-products (RAGE)
- Receptor of advanced glycation end-products (RAGE), 23
- S**
- SBP *See* Systolic blood pressure (SBP)
- Signaling mechanisms
 - AGEs, 23
 - artery inflammation, 22
 - NO, 22
 - oxidative stress, 21–22
 - TGF-β1, 23
- SOD antioxidant defense system *See* Superoxide dismutase (SOD) antioxidant defense system
- Sodium restriction
 - blood pressure, 49
 - physiological systems, body, 48
 - public health recommendations, 49
- SphygmoCor applanation device, 8
- Strength training
 - aerobic exercise, 34
 - exercise modality, aging, 33
 - left ventricular mass and hypertrophy indices, 34
 - vs. sedentary controls, 34
- Superoxide dismutase (SOD) antioxidant defense system, 21
- Supplementation en Vitamines et Mineraux Antioxydants (SU.VI.MAX) study, 32
- Systolic blood pressure (SBP), 5
- T**
- Transforming growth factor beta 1 (TGF-β1), 23
- V**
- Vascular smooth muscle cells (VSMCs), 5, 6, 20
- VSMCs *See* Vascular smooth muscle cells (VSMCs)
- W**
- Weight loss
 - aPWV reduction, 53
 - normotensive overweight/obese young adults, 52
 - plasma endothelin-1, 53